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Background: The mechanism underlying the differential cytotoxicity of curcumin in various cancer types, however,
remains largely unclear. The aims of this study is to examine the concentration- and time-related effects of curcumin
on two different breast cancer cells, MCF-7 and MDA-MB-231, and investigated the functional changes induced by
curcumin treatment, as well as their relationship to the PI3K/Akt-SKP2-Cip/Kips pathway.
Methods: First, WST-1 and clonogenic assay were performed to determine the cytotoxicity of curcumin in MCF-7 and
MDA-MB-231 cells. Then, the expression of CDK interacting protein/Kinase inhibitory protein (Cip/Kips) members (p27,
p21 and p57) and S-phase kinase-associated protein-2 (SKP2) was investigated by QRT PCR and Western Blotting.
Curcumin’s effect on PI3K (phosphatidylinositol 3-kinase) /Akt and its substrates Foxo1 and Foxo3a were then studied
by Western Blotting. Small interfering RNAs (siRNAs) targeting SKP2 was used to explore the relationship between SKP2
and Cip/Kips members. Finally, WST-1 assay was tested to explore the concomitant treatment with curcumin and the
inhibition of PKB or SKP2 signaling on curcumin sensitivity in MCF-7 and MDA-MB-231 cells.
Results: We demonstrated MCF-7 and MDA-MB-231 cells exhibited differential responses to curcumin by WST-1 and
clonogenic assay (MDA-MB-231 cells was sensitive, and MCF-7 cells was resistant), which were found to be related to
the differential curcumin-mediated regulation of SKP2-Cip/Kips (p21 and p27 but not p57) signaling. The differential
cellular responses were further linked to the converse effects of curcumin on PI3K/Akt and its substrates Foxo1 and
Foxo3a. Importantly, PI3K inhibitor wortmannin could counteract both curcumin-induced phosphorylation of Akt and
up-regulation of SKP2 in MCF-7 cells. Subsequent WST-1 assay demonstrated concomitant treatment with curcumin
and wortmannin or SKP2 siRNA not only further augmented curcumin sensitivity in MDA-MB-231 cells but also
overcame curcumin resistance in MCF-7 cells.
Conclusions: Our study established PI3K/Akt-SKP2-Cip/Kips signaling pathway is involved in the mechanism of action
of curcumin and revealed that the discrepant modulation of this pathway by curcumin is responsible for the
differential susceptibilities of these two cell types to curcumin.
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Breast cancer remains the most common type of cancer
in Asia. Despite displaying similar clinic pathological
features, however, patients typically respond differently
to therapies and display significantly different outcomes,
indicating the substantial diversity of the various cancer
subtypes. Indeed, genomic, epigenetic, transcriptional,
and proteomic analyses have revealed that breast cancer
subtypes may differ in pathway activity, progression,
and response to therapy [1]. Thus, a better understand-
ing of the molecular mechanisms that impact patient
response and resistance to candidate therapeutics may
be helpful in predicting clinical response and developing
more effective treatments for different subtypes of
breast cancer.
Curcumin is a popular phytochemical that is used as a
dietary additive. In Asia, dietary curcumin intake is very
high; adults consume up to 200 mg, or 7-8 μmol/kg of
body weight, per day [2]. Curcumin has repeatedly been
reported to be efficient and safe for the prevention and
treatment of a wide spectrum of pathological condi-
tions, including cancer [3,4]. Mounting evidence sug-
gests that the anti-tumor activity of curcumin may be
attributed to its ability to induce apoptosis and arrest
cell growth via pleiotropic mechanisms [3,5,6]. How-
ever, recent studies have also challenged the practice of
dietary curcumin supplementation in cancer patients
undergoing chemotherapy, including breast cancer pa-
tients [7,8], suggesting that it is necessary to first estab-
lish the benefit-risk profile of curcumin [9]. Moreover,
clinical trial data has indicated that patients respond dif-
ferently to curcumin, which may be due to the differen-
tial molecular signaling that underlies distinct subtypes
of cancer.
Considerable evidence exists demonstrating the roles
of cell-cycle mediators in determining a cell’s fate toward
proliferation, arrest, differentiation, quiescence, or apop-
tosis. The roles of members of the Cip/Kips family of
cyclin-dependent kinase inhibitors (CDKi), such as p21
CIP1/WAF1/CDKN1A, p27 KIP2/CDKN1B, and p57
KIP2/CDKN1C, in negatively regulating the cell cycle
and in genomic stability, apoptosis, senescence and
DNA repair have been well characterized [10,11]. Their
functional changes may be associated with the differen-
tial susceptibilities of different cancer subtypes to anti-
cancer drugs. However, the roles of members of the Cip/
Kips family (p27, p21, and p57) in mediating cellular re-
sponses to curcumin in different subtypes of breast can-
cer cells remains widely unknown.
SKP2 is the specific substrate-recognition subunit of
the SKP1 Cullin-F-box protein (SCF) type ubiquitin lig-
ase complex. SKP2 has emerged as an important player
in cell fate decisions by mediating the degradation of
specific substrates, including members of the Cip/Kipsfamily (p27, p57, and p21), p130, and c-Myc [12,13].
SKP2 is considered to have strong independent prog-
nostic potential and be a useful target for the treatment
of breast cancer [14,15]. SKP2 alterations have also been
found to be key mediators that are involved in cancer
growth and drug resistance [16-18]. Although the mech-
anisms that regulate SKP2 protein levels and how the
protein differentially modulates the susceptibilities of
different breast cancer cell types to chemotherapeutic
drugs, such as curcumin, are not clearly understood, the
PI3K/Akt survival pathway has been stated to be closely
associated with the functions of SKP2. Lin et al. and
Gao et al. reported that Akt-mediated phosphorylation
of SKP2 at Ser-72 impaired its degradation and re-
localized it to the cytosol, contributing to its oncogenic
functions [19,20]. In contrast, Boutonnet et al. and
Bashir et al. reported that phosphorylation of SKP2 on
Ser-72 did not control SKP2 binding to SKP1 and CUL1
and had no influence on SCFSKP2 ubiquitin ligase ac-
tivity and its subcellular localization [21,22]. Despite
these conflicting reports, the results of these studies im-
plied that activation of the PI3K/Akt pathway plays a
positive role in stabilizing SKP2 and thereby promoting
its oncogenic activities in regulating cell cycle progres-
sion, senescence and metastasis. Interestingly, the re-
sults of a recent study revealed that the SKP2 SCF
complex was a critical E3 ligase for ErbB-receptor-
mediated Akt ubiquitination, activation and membrane
recruitment, and that SKP2 deficiency inhibited Akt acti-
vation and Glut1 expression, leading to repression of
breast cancer development [23]. These findings imply that
a positive feedback loop composed of SKP2 and Akt
promotes cancer cell progression through the restriction
point. Furthermore, inhibition of the PI3K/Akt pathway
by LY294002 was reported to result in p27 accumulation,
which was associated with a decrease in SKP2 levels in
MCF-7 cells [24]. However, whether curcumin regulates
SKP2 expression via this pathway in breast cancer remains
unknown.
The present study aimed to seek the signaling pathway re-
sponsible for the differential susceptibilities of two different
breast cancer cell lines, MCF-7 and MDA-MB-231, to the
cytotoxic effects of curcumin. The concentration- and time-
related roles of curcumin in modulating the distinct cellular
responses of Cip/Kips proteins (p21, p27 and p57) and their
upstream effectors, SKP2 and PI3K/Akt, were systematically
examined. The interactions between these signaling mole-
cules were further investigated in an effort to explain why
MDA-MB-231 cells were sensitive, whereas MCF-7 cells
were resistant, to curcumin treatment. The factors, such as
SKP2 and Akt, that governed sensitivity to curcumin, espe-
cially in the curcumin-resistant MCF-7 cells, were subse-
quently evaluated. The results of the present study thus
expanded our knowledge of the PI3K/Akt-SKP2-Cip/Kips
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way in overcoming the drug (curcumin) resistance that is
commonly observed in different subtypes of breast cancer.
Results
The cytotoxicity of curcumin differs in MCF-7 and
MDA-MB-231 cells
The concentration- (2, 4, 6, 8, 10, 20, 30, and 40 μM) and
time-related (12 and 24 h) cytotoxicity of curcumin
against MCF-7 and MDA-MB-231 cells was assessed
using the WST-1 assay. Although similar changes in via-
bility were observed, the sensitivities of both tumor cell
lines to curcumin differed (Figure 1). Curcumin was found
to be effective at a concentration of 6 μM and to result in
a loss of approximately 80% of cell viability at a concentra-
tion of 40 μM after a 24 h treatment period in MDA-MB-
231 cells (Figure 1A). In contrast, curcumin had no
apparent effect, even at a concentration of 10 μM, and led
to only an approximately 35% reduction in cell viability at
a concentration of 40 μM after a 24 h treatment in MCF-7
cells (Figure 1A). The results revealed that these twoFigure 1 Curcumin’s responsiveness of MCF-7 and MDA-MB-231 cells. (
treatment. The indicated breast cancer cells were treated with indicated conc
represents the fluorescent changes (n = 3). The experiments were performed
curcumin treatment. The indicated breast cancer cells were treated with 40 μ
density (2,000 per well in 6 well plate). After 7–12 days, formed colonies were
condition. Represented is the percentage of viable clones after curcumin trea
determinations; bars, SD.different breast cancer cell lines displayed differential sus-
ceptibilities to curcumin-induced cytotoxicity.The clonogenic ability of MCF-7 and MDA-MB-231 cells
differs following curcumin treatment
To further examine the cytotoxic effects of curcumin over
a prolonged period of time, clonogenic assays were per-
formed on both of the cell lines 7 or 12 days after treat-
ment with 40 μM curcumin for 3 or 6 h, respectively.
DNA analyses of the stained colonies revealed that curcu-
min treatment for both 3 and 6 h thoroughly abrogated
the clonogenic ability of MDA-MB-231 cells (Figure 1B).
In MCF-7 cells, however, the same concentration of cur-
cumin did not significantly affect the capacity of the cells
to form viable colonies after 3 h of treatment and only
caused a slight decrease in the number of colonies after
6 h of treatment (Figure 1B). The results were consistent
with the findings in the cell viability assays and further
confirmed the differential responses of MCF-7 and MDA-
MB-231 cells to curcumin.A)WST-1 assay of MCF-7 and MDA-MB-231 cells after curcumin
entrations of curcumin for 12 or 24 h as described in the text. Data
three times. (B) Clonogenic analysis of MCF-7 and MDA-MB-231 cells after
M curcumin for 3 or 6 h, trypsinized, and plated in duplicates at low
stained with crystal violet. Clones in a given area were counted for each
tment respective to untreated cells. Columns, mean of three independent
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cells to curcumin are associated with differential
regulation of p27 and p21
To investigate the possible molecular mechanisms
underlying the differential responses of MCF-7 and
MDA-MB-231 cells to the cytotoxic effects of curcumin,
changes in the expression levels of several important
proteins from the CDKi family (i.e., p21, p27 and p57)
were examined after curcumin treatment. Marked in-
creases in p27 and p21, which were dependent upon the
curcumin doses and incubation times, were observed in
the curcumin-sensitive MDA-MB-231 cells (Figure 2). In
contrast, the effects of curcumin were less pronounced
in the curcumin-resistant MCF-7 cells, and significant
p27 and p21 accumulation only occurred at higher con-
centrations and after longer durations of treatment with
curcumin (Figure 2). Unexpectedly, no significant varia-
tions in p57 were observable in MCF-7 and MDA-MB-
231 cells (Figure 2), suggesting that p57 was not
involved in curcumin-induced cytotoxicity. Collectively,
these results suggested that the differential cellular re-
sponses to curcumin might be closely associated with its
differential regulation of p27 and p21, but not p57, in
MCF-7 and MDA-MB-231 cells.
Curcumin-induced down regulation of SKP2 protein and
mRNA levels is involved in the induction of p27 and p21
Interestingly, the sequential decreases in both SKP2 pro-
tein and mRNA levels also differed markedly between
the cell lines studied (Figure 3). In MDA-MB-231 cells,
suppression of SKP2 was dependent upon the curcumin
dose (Figure 3A) and treatment time (Figure 3B). Not-
ably, significant suppression of SKP2 was observed after
3 h and continued through 24 h of curcumin treatment
(Figure 3B). In MCF-7 cells, however, significant de-
creases in SKP2 were only observed with 30 or 40 μM
curcumin (Figure 3A) after 12 and 24 h (Figure 3B) of
curcumin treatment. In fact, obvious elevations in SKP2
were observed in MCF-7 cells that had been treated with
40 μM curcumin for 3 and 6 h (Figure 3B). In contrast,
the QRT-PCR results revealed that curcumin also tran-
scriptionally down-regulated SKP2 in a dose-related
manner in both cell types, but curcumin only readily
gave rise to an inhibitory effect on SKP2 in MDA-MB-
231 cells, even at a lower concentration (10 μM)
(Figure 3C). Collectively, these findings revealed that the
differential responses of the two cell types to curcumin
could be attributed to the differential modulation of p27,
p21 and SKP2, and those possible interactions between
the induction of p27 and p21 and the suppression of
SKP2 may be caused by curcumin treatment. Indeed, it
was further demonstrated in the present study that
SKP2 gene knockdown in MCF-7 and MDA-MB-231
cells resulted in significant increases in p27 and p21(Figure 4), supporting the idea that curcumin-mediated
SKP2 down-regulation was highly responsible for the in-
duction of p27 and p21.
Curcumin differentially affects the expression and activity
of PKB and its substrates in MCF-7 and MDA-MB-231 cells
Akt is one of the key determinants of cellular sensitivity to
chemotherapeutic drugs and plays a critical role in SKP2
regulation in various cell types at both the transcriptional
and post-transcriptional levels [19,25,26]. To examine the
interaction between Akt and SKP2, the phosphorylation
status of Akt was analyzed in MCF-7 and MDA-MB-231
cells after curcumin treatment. The results indicated that
curcumin inhibited the phosphorylation of Akt at Ser-473
in both a dose- and time-related manner (no obvious
effects on the expression of total Akt were observed)
(Figure 5A), which appeared to be well correlated with the
curcumin-induced changes in SKP2 in MDA-MB-231 cells
(Figure 3B). In contrast, MCF-7 cells exhibited a more
complex pattern of changes in Akt following curcumin
treatment (Figure 5A). In this cell line, treatment with
lower concentrations of curcumin (10, 20 and 30 μM) for
24 h caused mild increases, while treatment with 40 μM
caused a mild decrease, in Akt phosphorylation (Figure 5A).
In addition, the time-course (3, 6, 12 and 24 h) of treatment
with 40 μM curcumin gave rise to substantial increases in
Akt phosphorylation compared to the control in MCF-7
cells, although, notably, at the 24 h time point, 40 μM cur-
cumin readily induced an inhibitory effect on Akt activation
compared to that observed at the 3, 6 and 12 h time points
(Figure 5A). This pattern of changes in Akt, which was re-
lated to the concentration and time of curcumin treatment
in MCF-7 cells, was not correlated with the changes in
SKP2 (Figures 3A and B), implying the possible involve-
ment of other curcumin-targeted signaling pathways in the
modulation of SKP2 in this cell line. Indeed, the combined
treatment of MCF-7 cells for 6 h with curcumin and wort-
mannin, a selective PI3K inhibitor, counteracted both
curcumin-induced Akt phosphorylation and SKP2 up-
regulation, whereas the use of wortmannin alone or in
combination with curcumin did not further augment the
down-regulation of SKP2 as compared to the control
(Figure 5B). The results thus suggested that curcumin-
induced activation of Akt may be an important factor influ-
encing its ability to alter the activity of SKP2, thereby
promoting curcumin resistance in MCF-7 cells. Neverthe-
less, the definitive mechanism underlying the regulation of
SKP2 by p-Akt in curcumin-treated MCF-7 and MDA-
MB-231 cells requires further study.
In parallel to SKP2, the effects of curcumin on the
downstream targets of phospho-Akt, phospho-Foxo3a
and phospho-Foxo1 in MCF-7 and MDA-MB-231 cells
were also examined. As expected, continuous phosphor-
ylation of Foxo1 at Thr-24 and Foxo3a at Ser-318/321
Figure 2 (See legend on next page.)
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Figure 2 Analysis of Cip/Kips expression in response to curcumin in MCF-7 and MDA-MB-231 cells. (A) Analysis of p21 (1:1000), p27 (1:1000)
and p57 (1:500) changes induced by indicated concentration of curcumin for 24 h in MCF-7 and MDA-MB-231 cells was took by western blotting. Also
shown is a blot for β-actin as a loading control. The representative data of at least two independent experiments are shown. (B) Analysis of p21
(1:1000), p27 (1:1000) and p57 (1:500) changes induced by 40 μM curcumin for indicated time in MCF-7 and MDA-MB-231 cells was took by western
blotting. Also shown is a blot for β-actin as a loading control. The representative data of at least two independent experiments are shown. Quantitative
analysis of Cip/Kips protein expression using Quantity One software (Bio-Rad, USA). Graphs show quantification of Cip/Kips protein expression after
normalizing the data to respective control group.
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for 3, 6, 12, and 24 h, while in MDA-MB-231 cells, consti-
tutive phosphorylation of Foxo3a and Foxo1 was inhibited
by curcumin in a time-dependent manner (Figure 5C).
These results suggested the participation of another Akt
survival pathway by which MCF-7 cells escape cell death
through phosphorylation of FKHR family transcription fac-
tors, thus conferring curcumin resistance.
Treatment with a PKB inhibitor and SKP2 siRNA sensitizes
breast cancer cells to curcumin
To further explore whether the modulation of the Akt/
SKP2 signaling axis would eventually lead to phenotypic
changes in cellular susceptibilities to the cytotoxicity of
curcumin, viability assays on MCF-7 and MDA-MB-231
cells were again performed. Co-treatment with curcumin
and wortmannin revealed that the use of the Akt inhibitor
not only synergistically enhanced curcumin-induced cyto-
toxicity in both cell lines but also rendered MCF-7 cells
more susceptible to curcumin, similar to MDA-MB-231
cells (Figure 6A). Similarly, SKP2 knockdown also led to
the enhancement of curcumin toxicity in MCF-7 and
MDA-MB-231 cells (Figure 6B). Notably, the loss of cell
viability in SKP2-siRNA transfected MCF-7 cells was 1.5-
fold higher (63%) than that observed (38%) in the control-
siRNA transfected cells (Figure 6B), strongly suggesting
that curcumin-induced SKP2 up-regulation plays an im-
portant role in resistance to cell death in MCF-7 cells.
Collectively, these results indicated that the differential
susceptibilities to the cytotoxicity of curcumin that were
observed in MCF-7 and MDA-MB-231 cells were highly
attributable to the differential modulatory activity of cur-
cumin on Akt/SKP2 signaling and that concomitant treat-
ment with inhibitors of the Akt/SKP2 pathway sensitized
both MDA-MB-231 and curcumin-resistant MCF-7 cells
to curcumin treatment.
Discussion
Cip/Kips family proteins, such as p21 and p27, are well
documented to function as both sensors and effectors of
multiple anti-proliferative signals, and the absence of
p21 and p27 has been linked to drug resistance in mul-
tiple human malignancies [27-29]. In breast cancer cells
specifically, multi-phytochemical induced cytotoxicity
has been revealed to be highly associated with p27 orp21 induction [30-32]. For instance, p21 and p27 are
greatly enhanced following curcumin (50 μM) treatment
for 3 h in MCF-7 cells [33]. Chiu et al. also demon-
strated that curcumin increased p21 independently of
p53 in MDA-MB-231 cells [34]. Similarly, while the re-
sults of our study demonstrated the effects of curcumin
on p21 and p27 in MCF-7 and MDA-MB-231 cells, we
further revealed, for the first time, that curcumin altered
p27 and p21 in concentration- and time-related manners
(Figure 2), which was in agreement with the differential
response patterns of the two cell types to the cytotox-
icity of curcumin (Figure 1). The curcumin-mediated
functional changes in p21 and p27 may thus provide a
molecular explanation as to why MCF-7 cells were re-
sistant, while MDA-MB-231 cells were sensitive, to the
cytotoxic effects of curcumin, which was also supported
by recent findings indicating that the dual knockdown of
the p21 and p27 genes lead to a significant suppression
of MCF-7 cell proliferation. However, it is worth noting
that our findings differed from an earlier report by Shao
et al., in which treatment with higher concentrations of
curcumin (up to 50 μM) for 72 h did not cause varia-
tions in p21, although multiple inhibitory effects were
observed after curcumin (50 μM) treatment for 4 days in
both MCF-7 and MDA-MB-231 cells [35]. This discrep-
ancy may be explained by the fact that the high curcu-
min concentration (50 μM) and prolonged treatment
time (72 h) that was used in their study have resulted in
extensive cell death.
Although we demonstrated in the present study that the
distinct changes in p21 and p27 in MCF-7 and MDA-MB-
231 cells may be linked to the differential susceptibilities
of the cell lines to the effects of curcumin, the upstream
signaling that affected p21 and p27 still remained elusive.
Given that SKP2 plays critical roles in mediating the
ubiquitin-dependent degradation of some cell-cycle pro-
teins, including p27, p21 and p57 [12,13], and that aber-
rant SKP2 expression may contribute to the progression
and development of a number of malignant tumors in
humans, the effects of curcumin on SKP2 and the molecu-
lar relationship between these effects and the differential
induction of p27 and p21 were further investigated in
MCF-7 and MDA-MB-231 cells. We found that in the
curcumin-sensitive MDA-MB-231 cells, curcumin signifi-
cantly downregulated the expression of SKP2 at both the
Figure 3 (See legend on next page.)
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Figure 3 Analysis of SKP2 at both protein and transcriptional level in response to curcumin. (A) Analysis of (1:1000) changes induced by indicated
curcumin for 24 h in MCF-7 and MDA-MB-231 cells was taken by western blotting. Also shown is a blot for GAPDH as a loading control. The representative
data of at least two independent experiments are shown. (B) Analysis of SKP2 (1:1000) changes induced by 40 μM curcumin for indicated time in MCF-7 and
MDA-MB-231 cells was took by western blotting. Also shown is a blot for GAPDH as a loading control. The representative data of at least two independent
experiments are shown. Quantitative analysis of SKP2 protein expression using Quantity One software (Bio-Rad, USA). Graphs show quantification of SKP2
protein expression after normalizing the data to respective control group. (C) MCF-7 or MDA-MB-231 cells were treated with indicated concentration of
curcumin for 24 h. The bar graph indicates the fold change of SKP2 mRNA level in curcumin treated cells compared with non-treated cells. One-way ANOVA
was studied, followed by Student’s t test. Each bar represents the mean± SD of three independent experiments. *,P <0.05; **,P <0.01, compared with control.
RT-Q-PCR, quantitative RT-PCR.
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the curcumin resistant MCF-7 cells, however, the suppres-
sion of SKP2 was only observed at higher concentrations
(30 or 40 μM) and after a longer duration (12 or 24 h) of
curcumin treatment (Figure 3B). In addition, a significant
increase in SKP2 appeared following 3 or 6 h curcumin
treatment (40 μM) (Figure 3B), indicating a deregulation
of this protein in this cell line. Such distinct patterns of
SKP2 in response to curcumin treatment were not only
well correlated with the differential cytotoxicity but also
with the alterations in p21 and p27 that were observed in
MCF-7 and MDA-MB-231 cells, suggesting an interaction
between SKP2 and p21/p27 that functionally governed the
susceptibility of the two different cell types to curcumin.
This interaction was further confirmed by the SKP2
siRNA assay, which revealed that SKP2 knockdown led to
significant elevations in p21 and p27 expression in both
MDA-MB-231 andMCF-7 cells (Figure 4), suggesting a
mechanistic dependency of the curcumin-induced eleva-
tions of p21 and p27 on the suppression of SKP2. Previous
studies have shown that antisense oligonucleotides against
SKP2 mRNA inhibited the proliferation of cancer cell lines
and increased the sensitivity of these cells to apoptotic
stimuli [36,37]. In particular, knockdown of SKP2 inFigure 4 Knockdown of SKP2 expression in MCF-7 and MDA-MB-231
cells were transfected with SKP2-SiRNA or negative SiRNA (control-SiRNA) f
expression was evaluated by western blotting. A protein level of p21 and p
for GAPDH as a loading control. The representative data of at least two indMCF-7 cells inhibited cell growth and enhanced the cyto-
toxic effects of epirubicin [38]. In addition, several studies
revealed that the defective regulation of SKP2 was the key
underlying cause of rapamycin resistance in multiple tu-
mors and that SKP2 levels are a key determinant of antitu-
mor responses to mTOR inhibitors [39]. While in line
with these observations, our findings further suggest that
the differential susceptibilities to the cytotoxic effects of
curcumin may be highly associated with the SKP2-Cip/
Kips (p21 and p27) pathway, as observed in both cell lines,
and that the deregulation of SKP2 and p21/p27 signaling
may be responsible for curcumin resistance, as observed
in MCF-7 cells. Furthermore, while a number of studies
have focused on quantitative changes, such as the fact that
the low levels of p27 in breast cancer cells were due to the
high expression of SKP2 [14,40], very little attention has
been paid to the relationship between p21 and p57 and
SKP2-mediated degradation in breast cancer cells. The
data from the present study further suggest a new possible
mechanism underlying curcumin-induced changes in
SKP2expression in MCF-7 and MDA-MB-231 cells that
may be an important determinant ofp21 and p27 stability
by reducing the rate of their SKP2-mediated degradation.
In addition, no changes in p57 were observed in MCF-7cells induced up-regulation of p27 and p21. MCF-7 or MDA-MB-231
or 24 h or 48 h, (NEG means control group). Down-regulation of SKP2
27 in all cells was examined by western blotting. Also shown is a blot
ependent experiments are shown.
Figure 5 Curcumin modulated different PI3K/Akt pathway in MCF-7 and MDA-MB-231 cells. (A) Analysis of p-Akt (1:5000), Akt (1:1000) changes
induced by indicated curcumin for 24 h or 40 μM curcumin for indicated time in MCF-7 and MDA-MB-231 cells was took by western blotting. (B) MCF-7
cells were treated with 1 μM concentration of wortmannin for 1 h prior to treatment with curcumin (40 μM) for 6 h. Expression of p-Akt (1:5000) and SKP2
(1:1000) in indicated condition was examined by western blotting. Also shown is a blot for GAPDH as a loading control. (C) Analysis of p-Foxo1 (1:1000)
and p-Foxo3a (1:1000) changes induced by 40 μM curcumin for indicated time in MCF-7 and MDA-MB-231 cells was taken by western blotting. Also
shown is blot for β-actin as a loading control. The representative data of at least two independent experiments are shown.
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(Figure 2), regardless of SKP2 knockdown (data not
shown), suggesting that the degradation of p57 in these
cell lines may occur independently of SKP2, which differs
from that observed in other types of tumors [41]. There-
fore, the extent of the functional dependency on SKP2 of
different Cip/Kips proteins (p27, p21, and p57) in different
breast cancer subtypes requires further study.
The constitutive or increased activity of the PI3K/Akt-
dependent signaling cascade presents a major means by
which cancer cells achieve uncontrolled proliferation, inva-
sion, angiogenesis and drug resistance [42,43]. Akt signaling
has also been reported to play a critical role in SKP2 regula-
tion in various cell types at both the transcriptional and
post-translational levels [19,25,27]. To examine the inter-
action between Akt and SKP2, the phosphorylation status
of Akt inMCF-7 and MDA-MB-231 cells after curcumin
treatment was analyzed in this study. We demonstrated
that in MDA-MB-231 cells curcumin could markedly in-
hibit the phosphorylation of Akt at Ser-473 in both a dose-
and time-dependent manner (Figure 5A), which was inagreement with the changes that we observed in the ex-
pression pattern of SKP2 (Figures 3A and B), indicating that
the inhibitory effects of curcumin on SKP2 may be highly
related to the inhibitory role of curcumin in Akt activation.
In MCF-7 cells, however, curcumin treatment caused a
substantial increase in Akt phosphorylation, which exhib-
ited a pattern that substantially differed from that of Akt
in MDA-MB-231 cells (Figure 5A). Moreover, Akt phos-
phorylation at Ser-473 was unexpectedly observed to be
maintained at high levels over the various curcumin con-
centrations or treatment times in MCF-7 cells (Figure 5A),
which did not correspond to the curcumin-induced
changes inSKP2 (Figures 3A and B). The present results
demonstrated that curcumin treatment with either a lower
concentration (10 or 20 μM) or a higher concentration
(40 μM) for a shorter period of time (3 or 6 h) resulted in
SKP2 up-regulation that could be attributed to Akt activa-
tion (Figures 3A, B and 5A). These results were confirmed
by the co-administration of curcumin with the selective
PI3K inhibitor, wortmannin, which reversed the phos-
phorylation of Akt and the up-regulation of SKP2 in
Figure 6 Cell viability assay for treatment of curcumin with PKB inhibitor or SKP2 SiRNA. (A)Wortmannin alters curcumin response in MCF-7 and
MDA-MB-231 cells. MCF-7 and MDA-MB-231 cells were treated with 1 μM concentration of wortmannin for 1 h prior to treatment with curcumin (40 μM) for
12 h and WST-1 assay was performed as described in the “Materials and methods”. Each bar represents the mean ± SD of three independent experiments.
*,P <0.05; **,P <0.01, compared with control (DMSO). (B) Silencing of SKP2 increases cellular sensitivity to curcumin in MCF-7 and MDA-MB-231 cells. Cells
were seeded at a density of 5000 cells/well in 96-well plate and cultured overnight. Then the medium was replaced by 1%(V/V) FBS, 20nM SKP2-SiRNA and
control-SiRNA was added to indicated wells and cells were cultured for 48 h. SKP2-SiRNA transfection cells and control-SiRNA transfection cells were obtained.
Cells were treated with 40 μM curcumin for 12 h and WST-1 assay was performed to detect viability of cells. One-way ANOVA was studied, followed by
Student’s t test. Each bar represents the mean± SD of three independent experiments. *,P <0.05; **,P <0.01, compared with control (DMSO).
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centration of curcumin (30 or 40 μM) was used, the
resulting up-regulationof SKP2didnot occur in response
to the elevated Akt phosphorylation (Figures 3A, B and
5A), implying the involvement of another curcumin-
targeted signaling pathway, rather than merely Akt, which
predominantly modulates SKP2 expression. Indeed, recent
evidence has indicated a critical role of Focal Adhesion
Kinase (FAK) in the regulation of Cip/Kips through SKP2-
dependent and SKP2-independent mechanisms [44,45].
Whether the FAK-associated pathway is a direct target of
curcumin requires further investigation. With regard to
the interaction between Akt and SKP2 in breast cancer
cell lines, several previous studies have obtained data thatwere similar to our results, in which the treatment of
MCF-7 cells with inhibitor of PI3K (LY294002) was shown
to significantly decrease the expression of SKP2 [24], and
the use of rapamycin, an mTOR inhibitor, induced cyto-
toxicity via the suppression of SKP2 in MDA-MB-231
cells [46]. The present study further explored the idea that
the distinct behavior of the PI3K/Akt-SKP2 signaling path-
way in response to curcumin was highly associated with
the differential susceptibilities of MCF-7 and MDA-MB-
231 cells to the cytotoxic effects of curcumin, in which the
levels of Akt phosphorylation was an important factor in-
fluencing its ability to determine the activity of SKP2 and
thereby affected the responses of the breast cancer cells to
curcumin. This notion was validated by the results of the
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hibitor (wortmannin) or the down-regulation of SKP2
(SKP2 siRNA) not only augmented the sensitivity of the
curcumin-sensitive MDA-MB-231 cells, but more impres-
sively, also significantly enhanced the response of the
curcumin-resistant MCF-7 cells to curcumin treatment
compared to curcumin alone (Figure 6). Despite the fact
that the exact mechanism underlying the curcumin-
mediated regulation of SKP2 is not fully understood, the
present study illuminated the fact that the PI3K/Akt-SKP2
pathway functioned differentially in response to curcumin
in the two breast cancer subtypes and that the ability of
curcumin to inactivate SKP2-dependent signaling was im-
paired by the continuous Akt phosphorylation in the
curcumin-resistant MCF-7 cells, suggesting that the co-
administration of curcumin and PI3K- and/ or SKP2-
targeted inhibitors may be better alternatives in clinical
practice.
In addition to SKP2, the FKHR family transcription
factors (FOXO) have also been reported to be down-
stream targets of Akt that mediate apoptosis in breast
cancer [47]. FOXO activation promoted the transcrip-
tion of genes involved in cell cycle arrest and apoptosis
[48]. One mechanism by which Akt promotes cell sur-
vival is via FOXO phosphorylation, which inactivates
FOXO and prevents apoptosis [49,50]. Interestingly, we
also found that both Foxo1 and Foxo3a responded in
different manners to curcumin treatment in MCF-7 and
MDA-MB-231 cells. Curcumin treatment caused Foxo1
and Foxo3a dephosphorylation in MDA-MB-231 cells,
while Foxo1 and Foxo3a continued to be phosphory-
lated in MCF-7 cells (Figure 5C). Notably, the patterns
of Foxo1 and Foxo3a changes that were brought about
by curcumin treatment were in agreement with those
observed for p-Akt in MCF-7 and MDA-MB-231 cells,
suggesting that another Akt survival pathway modulated
the phosphorylation status of FOXO, which may also
explain why MDA-MB-231 cells were sensitive to cur-
cumin treatment, while MCF-7 cells were resistant.Conclusions
Our study established the importance of the PI3K/Akt-
SKP2-Cip/Kips signaling pathway and revealed that the
discrepant modulation of this pathway by curcumin was
highly responsible for the differential susceptibilities of
these two cell types to curcumin. Accordingly, the results
of the present study further suggested that p-Akt and
SKP2 are both important pharmacogenomic markers that
can be used to predict the sensitivity of breast cancer cells
to curcumin and that SKP2 silencing and p-Akt inhibition
may be potent therapeutic alternatives that can be used in
combination with curcumin to treat different breast can-
cer subtypes.Methods
Chemicals and reagents
Curcumin, with a purity ≥95%, was obtained from Unilever
R&D (Sanjivani Phytopharma Pvt. Ltd, India). Wortmannin
and dimethyl sulfoxide (DMSO) were purchased from
Sigma Chemical Co. (St. Louis, MO). DMEM GlutaMAX
medium containing L-Glutamine, and Leibovitz’s L-15
medium containing L-Glutamine and 0.05% Trypsin-EDTA,
were obtained from Gibco BRL (Grand Island, NY, USA).
FBS was obtained from PAA (Coelbe, Germany). Antibodies
that had been raised against S-phase kinase associated pro-
tein 2 (SKP2), p27 Kip1, p21 Waf1/Cip1, phospho-Foxo1
(Thr-24), p-Foxo3a (Ser-318/321), β-actin, GAPDH and an
anti-rabbit IgG antibody linked with HRP were purchased
from Cell Signaling Technology (Beverly, MA). Antibodies
that had been raised against Akt and p57 were obtained
from Bioworld (China). An antibody that had been raised
against p-Akt Ser-473 was obtained from Abcam
(Cambridge, UK).
Cell culture and curcumin treatment
MCF-7 cells were obtained from the American Type Cul-
ture Collection (ATCC, Rockville, MD). MDA-MB-231 cells
were purchased from Cell Bank of the Chinese Academy of
Sciences (Shanghai, China), where the cells were character-
ized by mycoplasma detection, DNA –Fingerprinting, isoen-
zyme analysisand cell vitality detection. All these cells were
maintained in American Type Culture Collection recom-
mended cell culture media andconditions. MCF-7 cells were
grown in DMEM medium containing 10% (V/V) FBS with-
out antibiotics at 37°C in a humidified atmosphere contain-
ing 95% air and 5% CO2. MDA-MB-231 cells were grown in
L-15 medium containing 10% (V/V) FBS without antibiotics
at 37°C. Curcumin was dissolved in DMSO to a stock con-
centration of 20 mM in a dark colored bottle at −20°C and
was diluted to the required concentration with medium
when needed. Prior to curcumin treatment, the cells were
grown to a density of approximately 80% and were then
treated with curcumin at different concentrations for the in-
dicated times. The control cells were incubated with DMSO
at the same final concentration.
Cell viability assay
Cell viability was determined in vitro using the water-
soluble tetrazolium WST-1 assay (Roche Molecular Bio-
chemicals, Mannheim, Germany). The cells were seeded
at a density of 10,000 cells/ well in 96 well plates and cul-
tured overnight. The cells were then treated with curcu-
min at various concentrations (2, 4, 6, 8, 10, 20, 30, and
40 μM) for 12 and 24 hours. Cells that were incubated
with an equivalent amount of DMSO without curcumin
served as controls. After the treatments, the medium was
aspirated and the cells were washed with PBS. Then, 10 μl
of WST-1 reagent was added to each well. The plates were
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After the incubation period, the plates were mixed gently
on an orbital shaker for one minute and the absorbance of
each sample was measured at 430 nm using a SpectraMax
M5 plate reader (Molecular Devices, Sunnyvale, CA).
Clonogenic assay
The breast cancer cells were plated in six-well plates over-
night and treated with 40 μM curcumin for a period of 3 or
6 h. After the removal of the drug-containing medium, the
cells were washed using PBS, trypsinized and plated at a
low density (2000 cells/ well in six-well plates). The cells
were then incubated with an equivalent amount of DMSO
without curcumin, which served as a control. The cells
were cultivated for 7 or 12d and the medium was refreshed
every two days. The colonies were stained with crystal vio-
let (Sigma Chemical Co, St. Louis, MO). The number of
clones in a given area was counted for each condition.
Quantitative real-time reverse transcription-PCR
Total RNA was extracted using Trizol reagent (Invitrogen,
USA). Two micrograms of RNA was reverse transcribed
using the Reverse Transcription System (Promega,
USA), according to the manufacturer’s recommended
instructions. The cDNA was diluted ten-fold prior to
PCR amplification. Real-time PCR was performed using
a FastSYBR Mixture (CWBIO, China). The primer pairs
that were used were as follows: SKP2, (forward) 5′-GC
TGCTAAAGGTCTCTGGTGT-3′, (reverse) 5′- AGGC
TTAGATTCTGCAACTTG-3′; and GAPDH, which
served as an internal control, (forward) 5′-TCTCTGC
TCCTCCTGTTC-3′ and (reverse) 5′-CTCCTGGAAG
ATGGTGATG-3′. The mRNA levels of SKP2 were
quantified by measuring the threshold cycle (Ct).
Western blotting
The cells were treated as described in the figure legends.
After the treatments, the cells were placed on ice, washed
with cold PBS and lysed in RIPA lysis buffer (Beyotime,
China) that had been supplemented with 1 mM PMSF, a
protease inhibitor cocktail and a phosphatase inhibitor
cocktail (KangChen, China). Cell lysates were centrifuged
at 14,000 × g at 4°C for 5 mins. Protein concentrations
were determined using a BCA kit (Beyotime, China). Ap-
proximately 40–50 μg of cellular protein from each sam-
ple was loaded onto 8% or 12% SDS-polyacrylamide gels
and electrotransferred to nitrocellulose (NC) membranes
(0.22/0.45 μm) (Millipore Billerica, USA). The blotted
membranes were incubated with different primary anti-
bodies, followed by incubations with secondary antibodies.
The proteins were visualized using an ECL kit (Millipore,
Billerica, USA). Relative protein levels were normalized to
β-actin/GAPDH. A Quantity One Gel Doc XR gel imagingsystem (Bio-Rad, USA) was used for the detection and
analysis of band intensity.
Specific RNA-mediated SKP2 down-regulation
Small interfering RNAs (siRNAs) targeting SKP2 were
purchased from Qiagen. For transient expression, the cell
lines were transfected using HiPerFect Transfection Re-
agent (Qiagen), as outlined in the HiPerFect Transfection
Reagent Handbook (Fifth edition, Qiagen). AllStars Nega-
tive siRNA AF 488 (Qiagen) was used both as a negative
control and to determine the transfection efficiency. Two
independent experiments were performed. SKP2 siRNA
data: the target sequence is 5′-AAGTGATAGTCATGC
TAAA-3′, the sense strand is 5′-GUGAUAGUGUCAUG
CUAAATT-3′ and the antisense strand is 5′-UUUAG
CAUGACACUAUCACTT-3′.
Statistical analyses
The values were expressed as the means ± SD. The statis-
tical significance of the mean values among the different
cell lines was determined using one-way ANOVA, followed
by Student’s t test.
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